AC Immune SA (ACIU) Stock Forecast
ACIU analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $8.64 average of analyst targets
- Upside to target
- +261.4% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.22
- 52-week range
- $2.12 – $3.84
ACIU analyst ratings
4 analystsNumber of analysts at each rating.
ACIU price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACIU earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.18 | −$0.13 | −$0.16 | +2.5% | 2 |
| Current fiscal year (2026) | −$0.41 | −$0.49 | −$0.35 | −$0.70 | +40.3% | 3 |
| Next fiscal year (2027) | $0.50 | −$0.70 | $2.05 | −$0.41 | +219.4% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACIU revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $206,250 | $0 | $825,000 | −78.0% | 4 |
| Current fiscal year (2026) | $18.7M | $16.2M | $21.2M | +422.4% | 3 |
| Next fiscal year (2027) | $89.2M | $0 | $265.0M | +377.9% | 4 |
ACIU EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACIU revenue: reported and forecast
ACIU EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.15 | −$0.15 | −$0.16 | −$0.16 | −9.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.48 | −$0.41 | −$0.41 | −$0.41 | −$0.41 | −12.9% | 0 up · 1 down |
| Next fiscal year (2027) | $0.26 | $0.50 | $0.50 | $0.50 | $0.50 | +89.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACIU earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACIU beat in 7 of 12.
What analysts expect from ACIU
4 analysts cover AC Immune; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.64, 261.4% above the latest close of $2.39. Analysts expect earnings of −$0.41 per share for 2026, +40.3% from a year earlier. For 2027 the average estimate is $0.50 per share on revenue of $89.2 million. AC Immune beat the EPS estimate in 7 of the last 12 quarters.
Related: ACIU income statement, ACIU key metrics, ACIU chart. See the ACIU stock overview for the latest quote and news.
ACIU forecast FAQ
What is AC Immune's price target?
The average analyst price target for AC Immune is $8.64, 261.4% above the latest close of $2.39.
Is AC Immune a buy, hold or sell?
Of 4 analysts covering AC Immune, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AC Immune's EPS forecast?
Analysts forecast −$0.41 per share for 2026 (range −$0.49 to −$0.35); for 2027 the estimate is $0.50.
What is AC Immune's revenue forecast?
The average revenue estimate for 2026 is $18.7 million, growth of 422.4%; for 2027 it is $89.2 million.
When does AC Immune report earnings?
AC Immune is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.22.
Does AC Immune usually beat earnings estimates?
AC Immune reported EPS at or above the analyst estimate in 7 of the last 12 quarters.